Article Text

PDF
Abatacept in spondyloarthritis refractory to tumour necrosis factor α inhibition
  1. I Olivieri1,
  2. S D’Angelo1,
  3. G A Mennillo1,
  4. G Pistone2,
  5. E Scarano3,
  6. A Padula1
  1. 1
    Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Potenza, Italy
  2. 2
    Rheumatology Unit, “Civico e Benfratelli” National Relevance and High Specialization Hospital Trust, Palermo, Italy
  3. 3
    Radiology Department of San Carlo Hospital of Potenza, Potenza, Italy
  1. Dr I Olivieri, Rheumatology Department of Lucania, Ospedale San Carlo, Contrada Macchia Romana, 85100, Potenza, Italy; ignazioolivieri{at}tiscalinet.it

Statistics from Altmetric.com

We report the case of a patient with undifferentiated spondyloarthritis (uSpA) who was successfully treated with abatacept after failing all three available tumour necrosis factor (TNF)α antagonists.

Her disease had begun in 2003 with right buttock pain and asymmetrical peripheral arthritis. Human leukocyte antigen (HLA) typing for the B27 antigen, antibodies to cyclic citrullinated peptide and rheumatoid factor were negative. No erosions were observed on x rays of hands and feet. Since MRI of the sacroiliac joints (SI) showed right sacroiliitis, a diagnosis of uSpA with axial and peripheral joint involvement was made.

During the first 4 years of evolution, the disease was unresponsive to different drugs including non-steroidal anti-inflammatory drugs (NSAIDs), oral and intra-articular …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.